Andre Esteva has been selected for the TIME 100 Health list of the world’s most influential people in health
OncoDaily GU · Pennsylvania
Visit company website
FULL-TIME
Posted Jul 10, 2026
Job Description
Career Updates
May 13, 2025 12:53 am
Andre Esteva/LinkedIn
Andre Esteva has been selected for the TIME 100 Health list of the world’s most influential people in health
Karen Knudsen, CEO Of Parker Institute For Cancer Immunotherapy, Shared a Post By Andre Esteva, Co-Founder And CEO At Artera, Adding
“This is so well deserved, Andre Esteva and Team Artera AI. I am grateful to serve as a Board Advisor, and most importantly for all that you are doing to match prostate cancer patients to the right therapy, the first time. This is precision medicine in action. Well done, Time Inc.”
Quoting Andre Esteva‘s Post
“Thank you TIME for selecting me for the TIME 100 Health list of the world’s most influential people in health.
It’s been a privilege to found and lead Artera AI – the work we are doing will save so many lives. Already our prostate cancer test, which helps identify which therapies patients would most benefit from, has been adopted by ~20% of prostate cancer clinicians just 5 quarters from launch.
We are in the NCCN Guidelines for the treatment of prostate cancer (National Comprehensive Cancer Network (NCCN)), reimbursed by Medicare (Centers for Medicare and Medicaid Services), covered by dozens of private payers (including Anthem, Inc.), and scaling in the US and abroad.
If you are attending this year’s American Society of Clinical Oncology (ASCO) meeting, drop by and see our various presentations on our work developing predictive AI tests for both prostate and breast cancer.Artera and I wouldn’t be here without the support of our many wonderful investors and advisors. So much gratitude.”
Stay Informed
Subscribe to OncoDaily Newsletter
Don't miss the latest news in oncology: stay up to date with daily picks from OncoDaily.
Subscribe
• Career Updates
American Society of Clinical Oncology Andre Esteva ASCO cancer Karen Knudsen OncoDaily Oncology TIME
May 13, 2025 12:53 am
Andre Esteva/LinkedIn
Andre Esteva has been selected for the TIME 100 Health list of the world’s most influential people in health
Karen Knudsen, CEO Of Parker Institute For Cancer Immunotherapy, Shared a Post By Andre Esteva, Co-Founder And CEO At Artera, Adding
“This is so well deserved, Andre Esteva and Team Artera AI. I am grateful to serve as a Board Advisor, and most importantly for all that you are doing to match prostate cancer patients to the right therapy, the first time. This is precision medicine in action. Well done, Time Inc.”
Quoting Andre Esteva‘s Post
“Thank you TIME for selecting me for the TIME 100 Health list of the world’s most influential people in health.
It’s been a privilege to found and lead Artera AI – the work we are doing will save so many lives. Already our prostate cancer test, which helps identify which therapies patients would most benefit from, has been adopted by ~20% of prostate cancer clinicians just 5 quarters from launch.
We are in the NCCN Guidelines for the treatment of prostate cancer (National Comprehensive Cancer Network (NCCN)), reimbursed by Medicare (Centers for Medicare and Medicaid Services), covered by dozens of private payers (including Anthem, Inc.), and scaling in the US and abroad.
If you are attending this year’s American Society of Clinical Oncology (ASCO) meeting, drop by and see our various presentations on our work developing predictive AI tests for both prostate and breast cancer.Artera and I wouldn’t be here without the support of our many wonderful investors and advisors. So much gratitude.”
Stay Informed
Subscribe to OncoDaily Newsletter
Don't miss the latest news in oncology: stay up to date with daily picks from OncoDaily.
Subscribe
• Career Updates
American Society of Clinical Oncology Andre Esteva ASCO cancer Karen Knudsen OncoDaily Oncology TIME
Additional Details
- State
- Pennsylvania
- Country
- US
Apply and matching require a free OVN account. Browse listings anytime without signing in.